A Consensus Plan for Action to Improve Access to Cancer Care in the Association of Southeast Asian Nations (ASEAN) Region

Mark Woodward

Abstract

In many countries of the Association of Southeast Asian Nations (ASEAN), cancer is an increasing problem due to ageing and a transition to Western lifestyles. Governments have been slow to react to the health consequences of these socioeconomic changes, leading to the risk of a cancer epidemic overwhelming the region. A major limitation to motivating change is the paucity of high-quality data on cancer, and its socioeconomic repercussions, in ASEAN. Two initiatives have been launched to address these issues. First, a study of over 9000 new cancer patients in ASEAN - the ACTION study - which records information on financial difficulties, as well as clinical outcomes, subsequent to the diagnosis. Second, a series of roundtable meetings of key stakeholders and experts, with the broad aim of producing advice for governments in ASEAN to take appropriate account of issues relating to cancer, as well as to generate knowledge and interest through engagement with the media. An important product of these roundtables has been the Jakarta Call to Action on Cancer Control. The growth and ageing of populations is a global challenge for cancer services. In the less developed parts of Asia, and elsewhere, these problems are compounded by the epidemiological transition to Western lifestyles and lack of awareness of cancer at the government level. For many years, health services in less developed countries have concentrated on infectious diseases and mother-and-child health; despite a recent wake-up call (United Nations, 2010), these health services have so far failed to allow for the huge increase in cancer cases to come. It has been estimated that, in Asia, the number of new cancer cases per year will grow from 6.1 million in 2008 to 10.6 million in 2030 (Sankaranarayanan et al., 2014). In the countries of the Association of Southeast Asian Nations (ASEAN), corresponding figures are 770 thousand in 2012 (Figure 1), rising to 1.3 million in 2030 (Ferlay et al., 2012). ASEAN consists of Brunei Darussalam, Cambodia, Indonesia, Lao, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Viet Nam. It, thus, includes low- and middle-income countries where the double whammy of infectious and chronic diseases will pose an enormous challenge in allocating limited resources to competing health issues. Cancer statistics, even at the sub-national level, only tell part of the story. Many individuals who contract cancer in poor countries have no medical insurance and no, or limited, expectation of public assistance. Whilst any person who has a family member with cancer can expect to bear some consequential burden of care or expense, in a poor family in a poor environment the burden will surely be greater. This additional burden from cancer is rarely considered, and even more rarely quantified, even in developed nations.

Keywords: Cancer incidence - cancer mortality - ASEAN

Policy Roundtable in Jakarta

In November 2012, a group of experts in the field was assembled in Jakarta, under the auspices of the ASEAN Foundation, to review the state of cancer treatment and services in ASEAN, with the exception of Brunei Darussalam and Singapore. This meeting produced the Jakarta Call for Action on Cancer Control (Box 1), which was subsequently endorsed at the Second Meeting of the ASEAN Task Force on Non-communicable Diseases (NCD) in Manila in October 2013. In broad terms, this document summarises the current situation in the cancer arena and articulates broad plans to strengthen health policy; prevention and early detection; diagnosis, treatment and palliative care; and surveillance and research. This builds upon the significant, but generally under-resourced and narrowly focused, programmes that already exist in member nations.

Shortfalls in Data

Perhaps the biggest obstacle to developing future
**Box 1. Jakarta Call for Action on Cancer Control**
policy in cancer care in ASEAN is the lack of reliable data and, for this reason, the Jakarta Call encourages the proliferation of cancer registries. The essential source of international statistics on cancer is GLOBOCAN (Ferlay et al., 2012), which (for 2012 data) places three ASEAN countries in the set of countries that, globally, have the worst quality data on cancer incidence, and four ASEAN countries in the set having the worst quality data on cancer mortality. National death registries are sometimes incomplete, cause of death may be made by unqualified arbitrators, such as through a verbal autopsy, and the range of cancers listed in official compilations may be limited (Kimman et al., 2012a; Moore et al., 2010a; Moore et al., 2010b). In contrast, Singapore has the best quality data of both types.

For most ASEAN countries, GLOBOCAN estimates of cancer incidence (such as those shown in Figure 1) and deaths (such as those shown in Figure 2) are based on data from other (‘similar’) countries or from subnational (typically urban) cancer registries. Statistics on the prevalence of cancer in ASEAN (excepting Brunei Darussalam and Singapore) are even more likely to be flawed, due to lack of national data on survival after a diagnosis. In addition, cancer prevents the living of a full life, which is not captured by "head counts", but data on the quality of life lived with cancer are lacking in ASEAN.

**The ACTION Study**

In order to address some of these knowledge gaps in most countries in ASEAN, the Action CosTs In ONcology (ACTION) study was launched in 2012 (Kimman et al., 2012b). This study selected consecutive patients with a first time diagnosis of cancer from 47 hospitals (general and specialist, public and private) within ASEAN, except Brunei Darussalam and Singapore. After exclusions due to patient or doctor refusals, 9513 patients were recruited into the study. The primary outcome for this study is financial catastrophe following treatment for cancer during the first year after diagnosis, defined as out-of-pocket expenditure exceeding 30% of household income. Secondary outcomes are survival, disease status, quality of life and psychological distress after one year. Funding to extend the study beyond a year is being sought.

**Policy Roundtable in Kuala Lumpur**

In order to track progress towards adoption of the principles of the Jakarta call to action, and the ACTION study, a further meeting of cancer experts was held in Kuala Lumpur on April 24/5, 2014. At this meeting participants had the opportunity to hear experiences of cancer control programmes in Indonesia, Japan and Thailand, to learn more about the ACTION study and see baseline results, to gain a better understanding of the burden of cancer worldwide and to discuss strategies to ensure cancer is a priority in government policies. A senior representative from the ASEAN Secretariat stressed the importance of identifying local champions to lead key activities and educate the public and other stakeholders about the importance of cancer control programmes through evidence-based policies. Breakout sessions were held in order to engage participants in small group discussions around strategies for establishing a framework for cancer policy development and programme management that could be adapted for various socioeconomic and cultural contexts in ASEAN.

Following the background presentations, attendees were divided into three working groups to discuss pre-defined specific issues, with a view to achieving a consensus on the way forward in a subsequent plenary session. The questions to be addressed and the results of these discussions follow.

**How can cross-country cooperation within ASEAN member states help them face the new reality of cancer care?**

An understanding of how to work within the ASEAN structure was seen as vital to the advancement of cancer care in the region. However, the group was concerned that the focus on cancer may be diluted within the ASEAN Non-Communicable Disease (NCD) Taskforce, since NCD covers a multitude of diseases. It was agreed that there needs to be better access to pharmaceuticals and health technology assessment, for example, in decision making around the human papillomavirus vaccine. It was further agreed that healthcare budgets would be more efficiently and effectively dispersed by sharing resources amongst member states.

The following actions were agreed:

- A roadmap should be established to guide member states on clear, concrete steps to engage policy...
stakeholders in their respective countries.

- Each country should develop its own work plan for cancer care. Common elements from these work plans would then be brought together to establish the overarching roadmap that is applicable to all member states.
- Evidence-based policies, cancer registries and research outcomes should be developed and strengthened.
- The ACTION study can become a basis for cancer advocacy.
- Public discourse on cancer should be encouraged through use of the media. It was noted, however, that the context in which the media operates varies across the ASEAN region, with press freedom more apparent in some countries than others.
- National champions should be identified, to meet under the umbrella of the ASEAN Secretariat which will lead cancer advocacy programmes in the region.
- A cancer registry network should be developed (Moore et al., 2014), where member states are able to transfer knowledge amongst themselves in terms of training, experience, best practices, sharing of resources, expertise and human resources.
- A specific cancer-type should be identified for a pilot project: lung cancer was unanimously agreed, since it is a leading type of cancer across ASEAN.

What is the value of public-private partnerships in improving outcomes in oncology and what are the conditions for the success of such partnerships?

A general example cited for public-private partnerships is a community intervention programme which surveys the public on their knowledge of the risk of cancer, and uses the information to formulate a cancer control programme. An example of a public-private partnership model in Malaysia was provided: public hospitals engage private oncology, services due to limited cancer care services in the public sector and the government refers patients from the public sector to receive treatment in private practice. Additionally, in Malaysia, hospices are scarce. Palliative care in the public sector is practically non-existent, prompting non-government organisations (NGOs) to take charge. Further, private clinics and NGOs in Malaysia offer some key services, such as cervical cancer screening, which the public sector is unable to provide. Similarly, in Cambodia NGOs organise home palliative care services for cancer patients. This ensures that care initiated in public sector hospitals can be continued at home.

The group opined that public-private partnerships are difficult to foster in the ASEAN region due to different operational systems in the public and private sectors. The group suggested a ‘build, operate and transfer’ mechanism, based on experiences in the Philippines. This would entail the private sector building a cancer care system, typically a hospital or healthcare facility, and managing the system until there is commercial success. The system would then be transferred to the public sector. To ensure success of public-private partnerships, the group agreed that the public sector must share data and information with the private sector in a transparent fashion. The sharing of information, however, must have strict guidelines. For example, an outline of each sector’s role, and how much information is to be released, should be agreed, so as to ensure successful partnerships.

How can we best mobilise stakeholders at the regional level?

Similar to working group 1, this group agreed that each country needs to establish its own cancer care system, since different countries have different levels of cancer support. Also in agreement with the first group, this group agreed that there should be a roadmap - a regional action plan providing a detailed framework for each country to improve cancer care systems. This road map should include:

- Data generation to support cancer care policies.
- Establishment of a National Cancer Institute in each country. This Institute should function as a cancer ‘hub’ that provides education, treatment, training, research and guidance in diagnosis.
- To make the roadmap a reality, the group agreed that cancer care programmes need to be endorsed by national governments at the top level, and that cancer needs to be recognised as a societal issue that is not confined to health. Stakeholders, mainly identified as Ministry of Health officials and grassroots communities, need science-based education and evidence-based toolkits to feel empowered and ultimately to be successful in gaining buy-in from governments. As a national agenda priority, a grassroots movement should be encouraged to provide a unified voice that creates a sense of urgency amongst government officials to recognise the importance of cancer. Additionally, the media should be mobilised to amplify the need for national cancer care programmes.

Plenary session

The expert group, as a whole, reached consensus that the following are needed:

- A concrete roadmap to guide member states in establishing local cancer control programmes, as well as an ASEAN regional cancer roadmap.
- More evidence-based toolkits and information, such as the ACTION study and the State of Oncology report (Boyle et al., 2013), for member states to use as advocacy materials to empower their respective government officials to raise cancer on the national agenda (Moore, 2013).
- Cross-country collaboration in terms of training and sharing of resources, to optimise the impact of cancer care in the region.
• Transparency in data collection and sharing of information between the public and private sectors, which is imperative to shape the cancer care agenda for the region.
• ASEAN countries should capitalise on the opportunity presented by the 12th ASEAN Health Ministers Meeting in September 2014, to elucidate the need for a regional cancer care roadmap as member states convene to discuss the ASEAN health agenda post-2015.
• A follow-up meeting in one year to further discuss the details of the roadmap, to help maintain momentum.

Conclusions

The current state of cancer care and prevention in ASEAN is incompatible with the socioeconomic changes taking place in the region. Mounting lifestyle-related cancer risks are fuelling a cancer epidemic that threatens to overwhelm the region unless governments take urgent action. The Jakarta call for action on cancer control and the ACTION study provide a rich foundation on which to build comprehensive, evidence-based cancer control programmes in the region, and provide important exemplars for other under-developed parts of the world. There is clear enthusiasm to capitalise on these initiatives amongst those who understand the huge burden conferred by cancer. The meeting of ASEAN cancer experts in Kuala Lumpur produced a strong consensus on the best ways forward, but the challenge now is to progress cancer control through advocacy of the cancer agenda at all levels of society and the development of sound, affordable policy guidelines.

Acknowledgements

Thanks to Dr Merel Kimman for producing Figures 1 and 2 and coordinating the ACTION study.

References


Appendix 1: Participants at the First Policy Roundtable Discussion on Future Access to Cancer Care in ASEAN (Jakarta, 23 Nov 2012)

Speakers
Dr. Peter Boyle, President, International Prevention Research Institute, Lyon, France
Dr. Panos Kanavos, London School of Economics, Social Policy and LSE Health, UK
Prof. Mark Woodward, The George Institute for Global Health, University of Sydney, Australia

ASEAN Foundation
Makarim Wibisono, Executive Director
Septania Hanawati, Head of Programs

ASEAN Secretariat
Dr. Surin Pitsuwan, Secretary General of ASEAN
Mr. Larry Maramis, Director for Cross-Sectoral Cooperation, and Dr. Ferdinal M. Fernando MD, MDM, Head, Health and Communicable Diseases Division, ASEAN Socio-Cultural Community

Cambodia
Dr. Yos Phanita, Deputy Director General, Ministry of Health
Dr. Prak Piseth Raingsey, Director, Preventive Medicine Department, Ministry of Health
Dr. Mao Reasey, Assistant Director General, Calmette Hospital

Indonesia
H.E. Dr. Nafsiah Mboi, Minister of Health
Dr. Ratna Rosita Hendardji, Secretary General, Ministry of Health
Prof. Dr Tjandra Yoga Aditama, SpP(K), MARS, DTCE, Director General, Disease Control and Environmental Health, Ministry of Health
Doddy Izwardi, Department of Health
Prof. Dr. Hasbullah Thabrany, Vice Head, Center of Economic and Health Policy, Public Health Faculty, University of Indonesia

Thailand
Mr. Larry Maramis, Director for Cross-Sectoral Cooperation, and Dr. Ferdinal M. Fernando MD, MDM, Head, Health and Communicable Diseases Division, ASEAN Socio-Cultural Community

Taiwan
Dr. Tung Yung-Chao, Deputy Minister of Health and Welfare, Ministry of Health and Welfare, Taiwan
Prof. Dr. Lu Chih-Chieh, Deputy Director General, Disease Control and Prevention, National Health Research Institute, Taiwan

Vietnam
Dr. Pham Thi Bu, Director General, National Cancer Institute
Dr. Trinh Xuan Ngoc, Director General, National Cancer Institute

Appendix 2: Participants at the Second Policy Roundtable Discussion on Future Access to Cancer Care in ASEAN (Kuala Lumpur, April 24/25, 2014)

Speakers

Dr. Pattarawin Attasara, Chief, National Cancer Database and Chief, Cancer Informatics, National Cancer Institute, Thailand

Prof. Peter Boyle, International Prevention Research Institute, France

Dr. Tomohiro Matsuda, Section Head (population based cancer registry), National Cancer Centre, Japan

Dr. Jintana Sriwongsa, ASEAN Secretariat

Prof. Hashullah Thabraney, Head, Center of Economic and Health Policy, University of Indonesia

Dr. Tran Van Thuan, Director, Institute of Cancer Prevention Research, Vietnam

Prof. Mark Woodward, George Institute for Global Health, University of Sydney, Australia/University of Oxford, UK

Miss Kajsa Wilhelmssson, Head, Health Policy and Market Access Europe & CIS, A&R Edelman (facilitator)

Cambodia

Dr. Prak Piseth Raingsey, Director, Preventive Medicine Department, MOH

Dr. Mao Reasey, Assistant Director General, Calmette Hospital

Dr. Thach Varouen, Deputy Director, Dept of Preventive Medicine, MOH

Prof. Eav. Sokha, Head, Dept Oncology and Hematology, Calmette Hospital

Dr. Chhom Sakborey, Calmette Hospital

Dr. Touch Socheat and Dr. Heng Viroath Oncologists, Khmer Soviet Friendship Hospital

Dr. Huy Meng Hut, Ministry of Health

Indonesia

Mrs. Sylvia Mardianna Sarwani, Indonesian Cancer Foundation

Dr. Tubagus Djumhana Atmakusuma, Head, Hematology and Medical Oncology Division, University of Indonesia

Dr. Esti Widiastuti, Head, Counselling and Evaluation Section, Sub Directorate of Cancer Control, Ministry of Health

Laos

Prof. Bouannack Saysanasongkham, Deputy General Director, Department of Health Care, Ministry of Health

Dr. Daovone Thepsouvanh, Head, Oncology Center

Prof. Bouannaphy Bounxouei, Director, Mahosot Hospital

Malaysia

Dr. Suleeporn Sanglajrang, Researcher, National Cancer Institute

Dr. Thiravud Khuhaprema, Director, National Cancer Institute

Dr. Wanchai Sattayawuthipong, Deputy Director General, Department of Medical Services, Ministry of Public Health

Dr. Wilawan Juengprasert, Director General, Department of Medical Services, Ministry of Public Health

Dr. Pattarawin Attasara, Chief, National Cancer Database and Chief, Cancer Informatics, National Cancer Institute

Thailand

Dr. Gloria Cristal-Luna, Head, Section of Medical Oncology, National Kidney and Transplant Institute

Dr. Melanie Coronel Santillan, Team Leader, Special Benefits Product Team, Philippine Health Insurance Corporation

Dr. Corazon Ngelangel, Principal Investigator, Philippine Cancer Society

Dr. Jennifer Raca, Senior Manager, Benefits Development and Product Team, Philippine Health Insurance Corporation

Dr. Saunthari Somasundaram, President and Medical Director, National Cancer Society

Miss Ranjit Kaur Pritam Singh, President, Together Against Cancer

Miss Yoon Sook Yee and Datin Dr. Amyza Saleh, Cancer Research Initiatives Foundation

Dr. Ho Gwo Fuang, Clinical Oncologist, University Malaya Medical Centre

Myanmar

Dr. Myo Khin, Primary Investigator and Dr. Win Pa Naing, Co-Investigator, Department of Medical Research

Prof. Htun Lwin Nyein, Co-Investigator, Department of Medical Research

Dr. Myo Myint Maw, Head, Medical Oncology Department, Yangon General Hospital

Miss Merla Rose Reyes, Senior Social Insurance Specialist, PhilHealth

Dr. Jennifer Raca, Senior Manager, Benefits Development and Research Department, PhilHealth

Mr. Michael Junsay, Pharmacist, National Center for Pharmaceutical Access Management, Department of Health

Mr. Michael Junsay, Pharmacist, National Center for Pharmaceutical Access Management, Department of Health